How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1

Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults after 3 or more treatments (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on their last treatment. It is only recommended if:

  • pomalidomide plus dexamethasone would otherwise be offered

  • the company provides teclistamab according to the commercial arrangement (see section 2).

1.2

This recommendation is not intended to affect treatment with teclistamab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.

Why the committee made these recommendations

The only treatment that is routinely used for relapsed and refractory multiple myeloma after 3 or more treatments is pomalidomide plus dexamethasone.

Teclistamab has not been directly compared in a clinical trial with pomalidomide plus dexamethasone. An indirect comparison suggests that teclistamab could increase how long people have before their cancer gets worse and how long they live compared with pomalidomide plus dexamethasone.

When considering the condition's severity, and its effect on quality and length of life, the most likely estimates are within the range that NICE considers an acceptable use of NHS resources. So, teclistamab is recommended if it is used only as an alternative to pomalidomide plus dexamethasone.